<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112681</url>
  </required_header>
  <id_info>
    <org_study_id>SARO.16.004.03.PROT</org_study_id>
    <nct_id>NCT03112681</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS)</brief_title>
  <acronym>EPICS</acronym>
  <official_title>A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zydus Discovery DMCC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zydus Discovery DMCC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study SARO.16.004.02 is a prospective, multicenter, randomized, double-blind,
      placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar
      magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis. A total 36 subjects will
      be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar
      magnesium 4 mg or placebo. The primary objective is to investigate the effect of a 16-week
      treatment regimen of Saroglitazar magnesium 2 mg and 4 mg on ALP levels in patients with
      Primary Biliary Cholangitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of a 16-week treatment regimen of Saroglitazar magnesium 2 mg and 4 mg on ALP levels in patients with Primary Biliary Cholangitis.</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Improvement in ALP levels after 16 weeks of Saroglitazar magnesium 2 mg and 4 mg treatment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Saroglitazar magnesium 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saroglitazar magnesium 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet Once daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar magnesium 2 mg</intervention_name>
    <description>Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.</description>
    <arm_group_label>Saroglitazar magnesium 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar magnesium 4 mg</intervention_name>
    <description>Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.</description>
    <arm_group_label>Saroglitazar magnesium 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females, between 18 and 75 years of age, inclusive.

          2. Patients on therapeutic doses of Ursodeoxycholic acid (UDCA) for ≥12 months and stable
             therapy for ≥3 months prior to enrolment.

          3. History of confirmed Primary Biliary Cholangitis Diagnosis, based on American
             Association for the Study of Liver Disease [AASLD] and European Association for Study
             of the Liver [EASL] Practice Guidelines; [Lindor 2009; EASL 2009], as demonstrated by
             the presence of at least≥2 of the following 3 diagnostic factors:

               -  History of elevated Alkaline Phosphatase levels for at least 6 months prior to
                  Screening Visit 1

               -  Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low
                  titer (&lt;1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or
                  antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid
                  dehydrogenase complex])

               -  Liver biopsy consistent with PBC.

          4. ALP ≥1.67x upper limit of normal (ULN) at Visit 1 and Visit 2 and with &lt; 30% variance
             between the levels from Visit 1 to Visit 2.

          5. Subjects must have a body mass index (BMI) within the range of 18 - 35 kg/m2.

          6. Contraception: Female patients must be postmenopausal, surgically sterile, or if
             premenopausal, agree to use ≥ 1 effective method of contraception during the trial.
             Effective methods of contraception are considered to be Hormonal (e.g., contraceptive
             pill, patch, intramuscular implant or injection); or Double barrier method, i.e., (a)
             condom (male or female) or (b) diaphragm, with spermicide; or Intrauterine device
             (IUD); or Vasectomy (partner).

          7. Must provide written informed consent and agree to comply with the trial protocol.

        Exclusion Criteria:

          1. Consumption of &gt;3 units of alcohol per day (&gt;21 units per week) if male and &gt;2 units
             of alcohol per day (&gt;14 units per week) if female for at least 3 consecutive months in
             the last 5 years (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of
             spirits/hard liquor).

          2. History or presence of other concomitant liver diseases including:

               -  Hepatitis B or C virus (HCV, HBV) infection

               -  Primary sclerosing cholangitis (PSC)

               -  Alcoholic liver disease

               -  Definite autoimmune liver disease or overlap syndrome

               -  Non-alcoholic steatohepatitis (NASH)

          3. Cirrhosis with complications, including history or presence of: spontaneous bacterial
             peritonitis, hepatocellular carcinoma, bilirubin &gt; 2x ULN, ascites, encephalopathy,
             known esophageal varices or history of variceal bleeding and active or history of
             hepatorenal syndrome.

          4. History of any venous thromboembolism, TIA, intracranial hemorrhage, neoplasm,
             arteriovenous malformation, vasculitis, bleeding disorder, coagulation disorders or
             screening blood tests that indicate altered coagulability (e.g. platelet count, aPTT,
             PTT or TT tests).

          5. Patients with baseline abnormal total bilirubin and INR.

          6. Patient with Gilbert's disease.

          7. Patients with &gt; 30% variance in the levels of AST, ALT, total bilirubin (TB) and INR
             from Visit 1 to Visit 2.

          8. Patients with mild, moderate and severe renal impairment i.e. estimated glomerular
             filtration rate (eGFR)&lt; 90 mL/min/1.73m2 at Visit 1 (calculated using Chronic Kidney
             Disease Epidemiology Collaboration (CKD-EPI) equation)..

          9. Abnormal total creatine kinase (CK), lipase and amylase at Visit 1.

         10. Unstable cardiovascular disease, including:

               -  unstable angina, (i.e., new or worsening symptoms of coronary heart disease
                  within the past 3 months), acute coronary syndrome within the past 6 months,
                  acute myocardial infarction in the past 3 months or heart failure of New York
                  Heart Association class (III - IV) or worsening congestive heart failure, or
                  coronary artery intervention, within the past 6 months

               -  history of (within prior 3 months) or current unstable cardiac dysrhythmias

               -  uncontrolled hypertension (systolic blood pressure [BP] &gt;160 mmHg and/or
                  diastolic BP &gt;100 mmHg)

               -  stroke or transient ischemic attack within the prior 6 months

         11. History of malignancy in the past 5 years and/or active neoplasm with the exception of
             resolved superficial nonmelanoma skin cancer.

         12. Contraindications to Saroglitazar magnesium or has any conditions affecting the
             ability to evaluate the effects of Saroglitazar magnesium.

         13. Patients who are on cerivastatin treatment at the time of enrolment.

         14. Known allergy, sensitivity or intolerance to the study drug, comparator or formulation
             ingredients.

         15. Participation in any other clinical study within the previous 3 months of screening.

         16. Illicit substance abuse within the past 6 months.

         17. History or other evidence of severe illness or any other conditions that would make
             the patient, in the opinion of the investigator, unsuitable for the study (such as
             poorly controlled psychiatric disease, human immunodeficiency virus (HIV), coronary
             artery disease or active gastrointestinal conditions that might interfere with drug
             absorption).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vimal Sanghavi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zydus Discovery DMCC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vimal Sanghavi, MD</last_name>
    <phone>+971 43998280</phone>
    <email>vimal.sanghavi@zydusdiscovery.ae</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deven Parmar, MD, FACP, FCP</last_name>
    <phone>91-9974252975</phone>
    <email>Deven.Parmar@zyduscadila.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raj Vuppalanchi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raj Vuppalanchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers NJ Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Pyrsopoulos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nick Pyrsopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sandra Atlas Bass Center for Liver Diseases- Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radica Palmer, NP-C</last_name>
      <phone>516-562-4563</phone>
    </contact>
    <investigator>
      <last_name>David E Bernstein, MD, FAASLD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Odin, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Shanti Mangar</last_name>
      <phone>212-241-0493</phone>
    </contact_backup>
    <investigator>
      <last_name>Joseph Odin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NY Presbyterian-Columbia</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Wattacheril, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julia Wattacheril, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Liver Diseases; New York Methodist Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Smruti Mohanty, MD, MS, FACP</last_name>
    </contact>
    <contact_backup>
      <last_name>Carolyn Payne</last_name>
      <phone>718-780-5282</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Sidney Barritt, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Renee Blanchard</last_name>
      <phone>919-843-5936</phone>
    </contact_backup>
    <investigator>
      <last_name>A. Sidney Barritt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew deLemos, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Elise Duffield</last_name>
      <phone>704-446-4835</phone>
    </contact_backup>
    <investigator>
      <last_name>Andrew deLemos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Goldberg, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Maureen McCauley</last_name>
      <phone>215-746-2575</phone>
    </contact_backup>
    <investigator>
      <last_name>David Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Einstein Medical Center Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Rossi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Simona Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009 Aug;51(2):237-67. doi: 10.1016/j.jhep.2009.04.009. Epub 2009 Jun 6.</citation>
    <PMID>19501929</PMID>
  </results_reference>
  <results_reference>
    <citation>Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308. doi: 10.1002/hep.22906.</citation>
    <PMID>19554543</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

